Product
Patisiran
Aliases
ALN-TTR02, ONPATTRO, patisiran (ALN-TTR02)
Name
Onpattro
INN Name
patisiran
FDA Approved
Yes
8 clinical trials
1 organization
11 indications
1 document
Indication
ATTR Amyloidosis With CardiomyopathyIndication
AmyloidosisIndication
HereditaryIndication
Transthyretin AmyloidosisIndication
TTR-mediated AmyloidosisIndication
Amyloid NeuropathiesIndication
FamilialIndication
Familial Amyloid PolyneuropathiesIndication
Transthyretin-RelatedClinical trial
Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) With CardiomyopathyStatus:
Clinical trial
HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)Status: Active (not recruiting), Estimated PCD: 2020-11-10
Clinical trial
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)Status: Completed, Estimated PCD: 2017-08-01
Clinical trial
An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver TransplantStatus: Completed, Estimated PCD: 2020-10-06
Clinical trial
APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)Status: Active (not recruiting), Estimated PCD: 2022-06-20
Clinical trial
A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients With TTR AmyloidosisStatus: Completed, Estimated PCD: 2013-10-01
Clinical trial
A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical StudyStatus: Completed, Estimated PCD: 2022-11-23
Clinical trial
Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With PolyneuropathyStatus:
Document
DailyMed Label: OnpattroOrganization
Alnylam Pharmaceuticals, Inc.